Prothena/$PRTA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Prothena

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Ticker

$PRTA
Sector
Health
Primary listing
NASDAQ

Employees

163

Headquarters

Dublin, Ireland
Website
www.prothena.com

Prothena Metrics

BasicAdvanced
$531M
-
-$5.63
-0.04
-

What the Analysts think about Prothena

Analyst ratings (Buy, Hold, Sell) for Prothena stock.

Bulls say / Bears say

Roche plans to advance prasinezumab, the anti-alpha-synuclein antibody licensed from Prothena, into Phase 3 trials for early-stage Parkinson’s disease by the end of 2025, backing the program after encouraging data from the Phase IIb PADOVA study (Roche)
The FDA has cleared the IND and granted Fast Track status to PRX123, Prothena’s dual Aβ/tau vaccine for Alzheimer’s disease, speeding up its clinical development (Business Wire)
Prothena finished Q2 2025 with $372.3 million in cash and restricted cash, ensuring sufficient capital to support ongoing trials and strategic plans into 2026 (Business Wire)
The Phase 3 AFFIRM-AL trial for birtamimab failed to achieve both its main and secondary goals, leading Prothena to end the program and lay off about 63% of its workforce as a cash-conservation measure (Business Wire)
Prothena’s GAAP revenue for the second quarter of 2025 plunged 96.7% from a year prior to $4.4 million, highlighting its lack of approved products and dependence on milestone payments from partners (Nasdaq)
In Q2 2025, Prothena recorded a GAAP net loss per share of $2.34, influenced by a $32.6 million restructuring charge, pointing to high cash burn and ongoing earnings volatility (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.

Prothena Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Prothena Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Prothena News

AllArticlesVideos
Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease

Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease

Business Wire6 days ago
Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PRTA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs